GlassScriptPhysician profile
Michael P Joyce
NPI 1205355211
$221.22
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $92.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.32 | 2021 | |
| Biogen, INC. | $22.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2022 | |
| Genentech USA, INC. | $15.77 | 2022 | |
| Amarin Pharma, INC. | $15.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.42 | 2022 | |
| Abbott Laboratories | $13.41 | 2021 | |
| Novo Nordisk INC | $13.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.